Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cymabay Therapeutics (CBAY)

Cymabay Therapeutics (CBAY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 326,330
  • Shares Outstanding, K 68,701
  • Annual Sales, $ 0 K
  • Annual Income, $ -72,550 K
  • 60-Month Beta 1.32
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.34

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.37
  • Number of Estimates 8
  • High Estimate -0.33
  • Low Estimate -0.40
  • Prior Year -0.34
  • Growth Rate Est. (year over year) -8.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.23 +12.29%
on 10/10/19
5.81 -18.24%
on 09/24/19
-0.86 (-15.33%)
since 09/18/19
3-Month
4.23 +12.29%
on 10/10/19
6.56 -27.59%
on 09/11/19
-1.68 (-26.13%)
since 07/18/19
52-Week
4.23 +12.29%
on 10/10/19
14.00 -66.07%
on 03/05/19
-6.06 (-56.06%)
since 10/18/18

Most Recent Stories

More News
CymaBay Therapeutics to Present at the H.C. Wainwright 3rd Annual NASH Investor Conference

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases...

CBAY : 4.75 (+3.49%)
CymaBay Therapeutics Announces Presentations at The Liver Meeting(R) 2019

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) today announced that two abstracts related to its seladelpar development program for the treatment of primary biliary cholangitis (PBC) will be presented at The...

CBAY : 4.75 (+3.49%)
CymaBay Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases...

CBAY : 4.75 (+3.49%)
CymaBay Therapeutics Announces Departure of Chief Medical Officer

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases...

CBAY : 4.75 (+3.49%)
CymaBay Therapeutics to Present at Upcoming Investor Conferences in September

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases...

CBAY : 4.75 (+3.49%)
CymaBay Reports Second Quarter 2019 Financial Results and Provides Corporate Update

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced financial...

CBAY : 4.75 (+3.49%)
CymaBay Therapeutics Strengthens Management Team with Appointment of Janet Dorling as Chief Commercial Officer

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced...

CBAY : 4.75 (+3.49%)
CymaBay Therapeutics to Report Second Quarter 2019 Financial Results on Wednesday, August 7

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it...

CBAY : 4.75 (+3.49%)
Options Traders Expect Huge Moves in CymaBay Therapeutics (CBAY) Stock

CymaBay Therapeutics (CBAY) needs investors to pay close attention to the stock based on moves in the options market lately.

CBAY : 4.75 (+3.49%)
CymaBay Reports First Quarter 2019 Financial Results and Provides Corporate Update

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced financial...

CBAY : 4.75 (+3.49%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade CBAY with:

Business Summary

CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based...

See More

Key Turning Points

2nd Resistance Point 4.98
1st Resistance Point 4.87
Last Price 4.75
1st Support Level 4.59
2nd Support Level 4.43

See More

52-Week High 14.00
Fibonacci 61.8% 10.27
Fibonacci 50% 9.11
Fibonacci 38.2% 7.96
Last Price 4.75
52-Week Low 4.23

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar